RxDoctor Payments Data

Enrique Huertas, MD

Cardiovascular Disease · Miami, FLNPI 1780679860

Payments from drug & device makers

$6,074in general payments, 2019–2025

Across 71 payments — averaging $85.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Biotronik Inc.$2K
  • Boston Scientific$933
  • Boehringer Ingelheim$186
  • Medtronic$161
  • Heartflow, Inc.$148
  • plus $537 from 8 others

What the payments were for

  • Food & beverage$6,074100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,074 in reported general payments places this provider in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$32,285
Medicare patients
108
Services billed
523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban331$381,775
MounjaroTirzepatide95$101,620
OzempicSemaglutide103$99,483
LinzessLinaclotide109$79,945
JanuviaSitagliptin Phosphate51$65,217
EntrestoSacubitril/Valsartan50$60,228
JardianceEmpagliflozin43$38,380
XareltoRivaroxaban36$37,207
FarxigaDapagliflozin Propanediol25$25,095
Tadalafil57$20,241
TradjentaLinagliptin16$13,582
TrulicityDulaglutide13$13,090
Atrovent HfaIpratropium Bromide27$12,589
CreonLipase/Protease/Amylase13$12,552
Fluticasone Propionate HfaFluticasone Propionate56$11,823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$132$381,775331 claims
NovartisEntresto$79$60,22850 claims
Boehringer IngelheimJardiance, Tradjenta$186$51,96259 claims
Johnson & JohnsonXarelto$18$37,20736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →